Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Cellebrite DI (CLBT) over the last 6 years, with Q3 2025 value amounting to -$3.3 million.

  • Cellebrite DI's Capital Expenditures fell 8252.75% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.4 million, marking a year-over-year decrease of 6274.84%. This contributed to the annual value of $8.6 million for FY2024, which is 6375.45% up from last year.
  • Per Cellebrite DI's latest filing, its Capital Expenditures stood at -$3.3 million for Q3 2025, which was down 8252.75% from -$3.6 million recorded in Q2 2025.
  • Cellebrite DI's 5-year Capital Expenditures high stood at $749000.0 for Q4 2021, and its period low was -$3.6 million during Q2 2025.
  • In the last 5 years, Cellebrite DI's Capital Expenditures had a median value of -$1.1 million in 2023 and averaged -$1.2 million.
  • As far as peak fluctuations go, Cellebrite DI's Capital Expenditures skyrocketed by 102469.14% in 2021, and later plummeted by 146962.03% in 2023.
  • Quarter analysis of 5 years shows Cellebrite DI's Capital Expenditures stood at $749000.0 in 2021, then tumbled by 285.71% to -$1.4 million in 2022, then plummeted by 62.47% to -$2.3 million in 2023, then plummeted by 40.62% to -$3.2 million in 2024, then fell by 4.53% to -$3.3 million in 2025.
  • Its last three reported values are -$3.3 million in Q3 2025, -$3.6 million for Q2 2025, and -$2.3 million during Q1 2025.